Dianthus Therapeutics Inc (DNTH) reported disappointing financial results for the third quarter of fiscal 2025, missing analyst estimates on both earnings and revenue. The company's earnings per share (EPS) stood at $-0.97, falling short of the consensus expectation of $-0.88 by $0.09. Similarly, revenue remained at $0.0B, which did not meet the anticipated figure of $0.0B.
The company, headquartered in New York City, focuses on developing complement therapeutics for patients with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage monoclonal immunoglobulin G4 designed for selective binding to the active form of C1s, with a pharmacokinetic profile aimed at supporting convenient self-administration.
Dianthus is currently conducting three mid- to late-stage clinical trials involving DNTH103 for conditions such as generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The company's market capitalization is approximately $1.55 billion, with a trailing twelve-month EPS of $-3.25.
Management will host an earnings conference call to discuss these results and provide further insights into the company’s performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's outcomes and future prospects.
Upcoming earnings reports are scheduled for May 10, 2026, and August 4, 2026, with EPS estimates of $-0.9231 and $-0.9224, respectively.